Alzheon Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$126M
- Investors
-
8
Alzheon General Information
Description
Developer of a small molecule-based drug discovery platform designed to treat Alzheimer's disease and other neurodegenerative disorders. The company's platform specializes in the development of oral inhibitors of amyloid neurotoxicity by inhibiting protein misfolding and aggregation based on individual genetic and biological information, enabling the healthcare industry to treat neurological disorders efficiently.
Contact Information
Website
www.alzheon.comCorporate Office
- 111 Speen Street
- Suite 306
- Framingham, MA 01701
- United States
Corporate Office
- 111 Speen Street
- Suite 306
- Framingham, MA 01701
- United States
Alzheon Timeline
Alzheon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series E) | 10-Feb-2025 | $126M | Completed | Clinical Trials - Phase 3 | ||
| 8. Later Stage VC (Series D) | 14-Apr-2022 | Completed | Clinical Trials - Phase 3 | |||
| 7. Grant | 20-Aug-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Grant | 15-Aug-2020 | Completed | Clinical Trials - General | |||
| 5. Debt - PPP | 03-May-2020 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC | 15-Jan-2020 | Completed | Clinical Trials - General | |||
| 3. IPO | 16-Jan-2019 | Cancelled | Clinical Trials - General | |||
| 2. Later Stage VC (Series B) | 05-Sep-2018 | $19.8M | $29.8M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 08-Apr-2015 | $10M | $10M | Completed | Clinical Trials - General |
Alzheon Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 4,622,227 | $0.001000 | $4.51 | $4.51 | 1x | $10.63 | 12.84% | |
| Series A | 8,175,303 | $0.001000 | $1.37 | $1.37 | 1x | $3.23 | 22.71% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Alzheon Comparisons
Industry
Financing
Details
Alzheon Competitors (86)
One of Alzheon’s 86 competitors is Nine Square Therapeutics, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nine Square Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| Cerecin | Venture Capital-Backed | Denver, CO | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| Mitobridge | Formerly VC-backed | Cambridge, MA |
Alzheon Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alzheon Patents
Alzheon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4514335-A1 | Tramiprosate for treating apoe4-related diseases | Pending | 28-Apr-2022 | ||
| AU-2023215421-A1 | Alz-801 for use in treating a covid-19 associated neurological symptom | Pending | 07-Feb-2022 | ||
| EP-4475831-A1 | Alz-801 for use in treating a covid-19 associated neurological symptom | Pending | 07-Feb-2022 | ||
| US-20250127734-A1 | Alz-801 for use in treating a covid-19 associated neurological symptom | Pending | 07-Feb-2022 | ||
| CA-3240392-A1 | Alz-801 for use in treating alzheimer's disease | Pending | 09-Dec-2021 | A61K31/16 |
Alzheon Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alzheon Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alerce Investment Management | PE/Buyout | Minority | ||
| Thornapple River Capital | Venture Capital | Minority | ||
| The National Institute on Aging (NIA) | Government | |||
| HCL Capital | Family Office | Minority | ||
| Angel (individual) | Minority |
Alzheon FAQs
-
When was Alzheon founded?
Alzheon was founded in 2013.
-
Where is Alzheon headquartered?
Alzheon is headquartered in Framingham, MA.
-
What is the size of Alzheon?
Alzheon has 31 total employees.
-
What industry is Alzheon in?
Alzheon’s primary industry is Drug Discovery.
-
Is Alzheon a private or public company?
Alzheon is a Private company.
-
What is Alzheon’s current revenue?
The current revenue for Alzheon is .
-
How much funding has Alzheon raised over time?
Alzheon has raised $212M.
-
Who are Alzheon’s investors?
Alerce Investment Management, Thornapple River Capital, The National Institute on Aging (NIA), HCL Capital, and are 5 of 8 investors who have invested in Alzheon.
-
Who are Alzheon’s competitors?
Nine Square Therapeutics, Cerecin, CuraSen, CervoMed, and Mitobridge are some of the 86 competitors of Alzheon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
